- Home
- KGEI vs IMMP Comparison
KGEI vs IMMP Comparison
Compare KGEI & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- IMMP
- Stock Information
- Founded
- KGEI 2008
- IMMP 1987
- Country
- KGEI United States
- IMMP Australia
- Employees
- KGEI N/A
- IMMP N/A
- Industry
- KGEI
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- KGEI
- IMMP Health Care
- Exchange
- KGEI Nasdaq
- IMMP Nasdaq
- Market Cap
- KGEI 254.9M
- IMMP 251.8M
- IPO Year
- KGEI N/A
- IMMP N/A
- Fundamental
- Price
- KGEI $5.56
- IMMP $2.08
- Analyst Decision
- KGEI Strong Buy
- IMMP Buy
- Analyst Count
- KGEI 1
- IMMP 1
- Target Price
- KGEI $11.00
- IMMP $7.00
- AVG Volume (30 Days)
- KGEI 123.4K
- IMMP 93.3K
- Earning Date
- KGEI 11-11-2025
- IMMP 10-10-2025
- Dividend Yield
- KGEI N/A
- IMMP N/A
- EPS Growth
- KGEI 35.27
- IMMP N/A
- EPS
- KGEI 0.54
- IMMP N/A
- Revenue
- KGEI $57,936,000.00
- IMMP $3,306,742.00
- Revenue This Year
- KGEI $14.07
- IMMP $16.82
- Revenue Next Year
- KGEI $26.69
- IMMP N/A
- P/E Ratio
- KGEI $10.28
- IMMP N/A
- Revenue Growth
- KGEI 6.52
- IMMP 31.28
- 52 Week Low
- KGEI $2.91
- IMMP $1.32
- 52 Week High
- KGEI $9.89
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- KGEI 47.89
- IMMP 72.79
- Support Level
- KGEI $5.15
- IMMP $1.75
- Resistance Level
- KGEI $5.73
- IMMP $1.89
- Average True Range (ATR)
- KGEI 0.23
- IMMP 0.08
- MACD
- KGEI -0.00
- IMMP 0.04
- Stochastic Oscillator
- KGEI 54.91
- IMMP 93.62
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.